Ecolab Inc Stock Price, News & Analysis

Ecolab has partnered with Manchester United to enhance the cleanliness and safety of the iconic Old Trafford stadium and Carrington training ground. The venue has been awarded the Ecolab Science Certified™ seal, highlighting its commitment to advanced hygiene practices for fans, players, and staff. Ecolab's cleaning solutions, used in high-traffic areas, serve nearly 2 million fans and 3,000 employees annually. This partnership underscores Ecolab's expertise in delivering science-based hygiene solutions, leveraging its experience from various sectors, including healthcare.

Ecolab Inc. announced the election of twelve director nominees for a one-year term at its annual stockholders' meeting. The shareholders also ratified the appointment of PricewaterhouseCoopers LLP as the independent accounting firm for 2022 and approved the executive compensation plan. A proposal regarding special meeting ownership was not approved. Ecolab, a leader in water, hygiene, and infection prevention solutions, reported annual sales of $13 billion and operates in over 170 countries.

The board of directors of Ecolab declared a quarterly cash dividend of $0.51 per share, payable on July 15, 2022. Shareholders must be on record by June 21, 2022. Ecolab has maintained a strong dividend history, having paid cash dividends for 85 consecutive years. With annual sales of $13 billion and over 47,000 associates, the company is a leader in water, hygiene, and infection prevention solutions, serving nearly three million locations globally.

Ecolab will conduct a virtual-only Annual Meeting of Stockholders on May 5, 2022, starting at 9:30 a.m. Central Time. Attendees can access the meeting via www.virtualshareholdermeeting.com/ECL2022. The meeting is expected to last approximately 30 minutes.

Stockholders must enter a 16-digit control number to participate, although guests can listen in without it. A replay of the webcast will be available until May 12, 2022.

Ecolab (ECL) announced a strong first quarter with reported sales increasing 13% year-over-year to $3.27 billion. Adjusted diluted EPS reached $0.82, up 1% from last year, despite a 10% decline in reported EPS to $0.60 due to rising costs from the war in Eastern Europe. Strong growth in the Institutional & Specialty segment drove sales, but healthcare sales contracted, reflecting prior year COVID-related demand. The company expects continued pricing momentum, with a projected 6% to 7% increase for the remainder of 2022, despite anticipated cost inflation and the rollout of an energy surcharge.